These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11060766)

  • 41. Efficacy and proarrhythmia of oral sotalol in pediatric patients.
    Pfammatter JP; Paul T; Lehmann C; Kallfelz HC
    J Am Coll Cardiol; 1995 Oct; 26(4):1002-7. PubMed ID: 7560592
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The coming of age of the class III antiarrhythmic principle: retrospective and future trends.
    Singh BN
    Am J Cardiol; 1996 Aug; 78(4A):17-27. PubMed ID: 8780325
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Ventricular cardiac arrhythmias. New anti-arrhythmia agents].
    Scholz H
    Z Kardiol; 1996; 85 Suppl 6():91-6. PubMed ID: 9064988
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparative study of electrophysiological mechanisms of anti-arrhythmia III class agents, cardiocyclide, nibentan, and sotalol during experimental myocardial infarction and sympathetic stimulation].
    Kaverina NV; Lyskovtsev VV; Popova EP
    Eksp Klin Farmakol; 2003; 66(1):27-33. PubMed ID: 12683077
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contribution of delayed ventricular repolarization to the anti-arrhythmic efficacy of sotalol.
    Brachmann J; Senges J; Lengfelder W; Jauernig R; Rizos I; Czygan E; Cobbe SM; Kübler W
    Eur Heart J; 1985 Nov; 6 Suppl D():171-4. PubMed ID: 3936715
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review.
    Hilleman DE; Bauman AL
    Pharmacotherapy; 2001 May; 21(5):556-75. PubMed ID: 11349745
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Class III antiarrhythmic agents: the next wave.
    Bauman JL
    Pharmacotherapy; 1997; 17(2 Pt 2):76S-83S; discussion 89S-91S. PubMed ID: 9085343
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Drug therapy of ventricular arrhythmias].
    Hohnloser SH
    Med Klin (Munich); 1997 Apr; 92(4):208-10. PubMed ID: 9221302
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.
    Singh BN; Deedwania P; Nademanee K; Ward A; Sorkin EM
    Drugs; 1987 Sep; 34(3):311-49. PubMed ID: 3315621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias.
    Lee RJ; Wong M; Siu A; Namekawa-Wong M; Epstein LM; Fitzpatrick AP; Grogin HR; Scheinman MM; Lesh MD
    Am Heart J; 1996 Nov; 132(5):973-8. PubMed ID: 8892770
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Results of sotalol (Darob) therapy in supraventricular tachyarrhythmias.
    Toporan D; Protopopescu T; Ioan A; Paraschiv A
    Rom J Intern Med; 1998; 36(3-4):207-17. PubMed ID: 10822517
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Usefulness of sotalol for life-threatening ventricular arrhythmias.
    Roden DM
    Am J Cardiol; 1993 Aug; 72(4):51A-55A. PubMed ID: 8346727
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A comparison of the efficacy of sotalol and nadolol in the suppression of ventricular ectopic beats.
    Myburgh DP; Smith R; Diamond TH; Faitelson HL; Sommers DK
    S Afr Med J; 1983 Feb; 63(8):263-5. PubMed ID: 6337412
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sotalol: from "just another beta blocker" to "the prototype of class III antidysrhythmic compound".
    Claudel JP; Touboul P
    Pacing Clin Electrophysiol; 1995 Mar; 18(3 Pt 1):451-67. PubMed ID: 7770366
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Azimilide dihydrochloride: a new class III anti-arrhythmic agent.
    Abrol R; Page RL
    Expert Opin Investig Drugs; 2000 Nov; 9(11):2705-15. PubMed ID: 11060832
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
    Antz M; Cappato R; Kuck KH
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):627-35. PubMed ID: 8569226
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Azimilide dihydrochloride: a unique class III antiarrhythmic agent.
    Tran HT
    Heart Dis; 1999; 1(2):114-6. PubMed ID: 11720612
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Theoretical possibilities for the development of novel antiarrhythmic drugs.
    Varró A; Biliczki P; Iost N; Virág L; Hála O; Kovács P; Mátyus P; Papp JG
    Curr Med Chem; 2004 Jan; 11(1):1-11. PubMed ID: 14754422
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study.
    Gelzer AR; Kraus MS; Rishniw M; Hemsley SA; Moïse NS
    J Vet Cardiol; 2010 Aug; 12(2):93-106. PubMed ID: 20663731
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute echocardiographic effects of sotalol on ventricular systolic function in dogs with ventricular arrhythmias.
    Visser LC; Kaplan JL; Nishimura S; Gunther-Harrington CT; Bélanger C; Oldach MS; Stern JA; Mueller MS
    J Vet Intern Med; 2018 Jul; 32(4):1299-1307. PubMed ID: 29968936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.